Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

334

HTML

2361

Figures (1-1)

386

Tables (1-3)

305

Sum=3386

Jun 7, 2007 (publication date) through May 14, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jun 7, 2007; 13(21): 2967-2972
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2967

Table 1 Baseline characteristics of patients n (%)

	OAC7 (n = 69)	OAC14 (n = 62)
Age (yr)	47.5 ± 16	45 ± 15
Male	27 (39.1)	18 (29)
Smokers	14 (20.3)	21 (33.9)
Previous antibiotic exposure
Betalactamics	56 (81.2)	51 (82.3)
Clarithromycin	13 (18.8)	18 (29)
Metronidazol	13 (18.8)	12 (19.4)
Tetracyclines	32 (46.4)	26 (41.9)
Endoscopic diagnosis
Ulcer disease	14 (20.3)	24 (38.7)
Non-ulcer disease	44 (63.8)	30 (48.4)
Normal	11 (15.9)	8 (12.9)

Citation: Riquelme A, Soza A, Pedreros C, Bustamante A, Valenzuela F, Otarola F, Abbott E, Arellano M, Medina B, Pattillo A, Greig D, Arrese M, Rollan A. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. World J Gastroenterol 2007; 13(21): 2967-2972
URL: https://www.wjgnet.com/1007-9327/full/v13/i21/2967.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i21.2967